Recent Innovations in Oral Contraception
| Autor: | Scarlett Phan-Weston, Miriam Cremer, Adam Jacobs |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Ovulation
Hirsutism Pediatrics medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism Levonorgestrel Ethinyl Estradiol Placebo Contraceptives Oral Hormonal Endocrinology Patient satisfaction Pregnancy Thromboembolism Physiology (medical) Acne Vulgaris medicine Humans Dosing Menstrual Cycle Menstruation Disturbances Randomized Controlled Trials as Topic Gynecology Estradiol business.industry Obstetrics and Gynecology Drospirenone Contraception Reproductive Medicine Family planning Pill Endometrial Hyperplasia Hyperkalemia Androstenes Female Uterine Hemorrhage business Progestin medicine.drug |
| Zdroj: | Seminars in Reproductive Medicine. 28:140-146 |
| ISSN: | 1526-4564 1526-8004 |
| DOI: | 10.1055/s-0030-1248139 |
| Popis: | Traditional forms of oral contraception contain 21 days of hormone-containing pills and 7 days of placebo during the hormone-free interval (HFI). Since 2003, the Food and Drug Administration has approved 24/4, 84/7, and 365-day regimens. These regimens shorten the HFI in an attempt to decrease bleeding and menstrual-associated side effects. Safety and efficacy of these regimens is comparable with traditional 21/7 dosing. Extended regimens are associated with high patient satisfaction. Bleeding patterns are similar or shorter in women using extended regimens, along with improvement in menstrual symptoms. One of the new formulations contains the new progestin drospirenone, which has antimineralocorticoid and antiandrogenic properties. This review summarizes the data about new formulations of oral contraception available in the United Sates and also provides a summary of the current literature on drospirenone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|